Serum CYFRA 21–1 is one of the most important serum markers in the diagnosis of non-small cell lung cancer (NSCLC), especially squamous-cell carcinoma. However, it remains unknown whether pretreatment serum CYFRA 21–1 values (PCV) may also have prognostic implications in patients with advanced lung adenocarcinoma.
Ono et al BMC Cancer 2013, 13:354 http://www.biomedcentral.com/1471-2407/13/354 RESEARCH ARTICLE Open Access Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study Akira Ono1*, Toshiaki Takahashi1, Keita Mori4, Hiroaki Akamatsu1, Takehito Shukuya1, Tetsuhiko Taira1, Hirotsugu Kenmotsu1, Tateaki Naito1, Haruyasu Murakami1, Takashi Nakajima2, Masahiro Endo3 and Nobuyuki Yamamoto1 Abstract Background: Serum CYFRA 21–1 is one of the most important serum markers in the diagnosis of non-small cell lung cancer (NSCLC), especially squamous-cell carcinoma However, it remains unknown whether pretreatment serum CYFRA 21–1 values (PCV) may also have prognostic implications in patients with advanced lung adenocarcinoma Methods: We retrospectively reviewed the data of 284 patients (pts) who were diagnosed as having advanced lung adenocarcinoma and had received initial therapy Results: Of the study subjects, 121 pts (43%) had activating epidermal growth factor receptor (EGFR) mutations (Mt+), while the remaining 163 pts (57%) had wild-type EGFR (Mt-) Univariate analysis identified gender (male/ female), ECOG performance status (PS) (0-1/ ≥2), PCV (